Publications & Presentations

Scientific publications and presentations reflect the quality of the innovative research being done by our scientists and clinical collaborators.

Immunomodulation and Pressure-Enabled Regional Immunotherapy

August 2020
Journal for ImmunoTherapy of Cancer
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
Katz SC et al.
June 2020
NCI Drug Dictionary
Definition of TLR9 Agonist SD-101
National Cancer Institute Accessed June 17, 2020
June 2019
American Society of Clinical Oncology (ASCO) Annual Meeting
Abstract No. 9534 Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870).
Milhem M, Long GV, Hoimes CJ, et al.
June 2019
American Society of Clinical Oncology (ASCO) Annual Meeting
Abstract No. 9555 Phase 1b/2, Open Label, Multicenter Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870).
Amin A, Long GV, Milhem M, et al.
June 2019
American Society of Clinical Oncology (ASCO) Annual Meeting
Abstract 6039 1b/2, Open Label, Multicenter Study of Intratumoral SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001/KEYNOTE-184, NCT02521870).
Cohen E, Nabell L, Ribas A, et al.
January 2019
Oncogene
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, Miller G, Espat NJ, Junghans RP, Katz SC.
October 2018
Cancer Discovery
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Ribas A et al.
October 2018
Cancer Discovery
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
Frank MJ et al.
October 2016
PNAS
Intratumoral Injection of a CpG Oligonucleotide Reverts Resistance to PD-1 Blockade by Expanding Multifunctional CD8+ T Cells
Wang S et al.
June 2016
Cancer Gene Therapy
Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M, Guha P, Cunetta M, Espat NJ, Miller G, Junghans RP, Katz SC.

Drug Delivery

January 2019
Cardiovascular and Interventional Radiology
End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
Joseph J. Titano, Aaron M. Fischman, Arnav Cherian, Madeline Tully, Lance L. Stein, Louis Jacobs, Raymond A. Rubin, Michael Bosley, Steve Citron, Dean W. Joelson, Roshan Shrestha, and Aravind Arepally
April 2018
Journal of Vascular and Interventional Radiology
Abstract No. 133 Surefire Infusion System (SIS) hepatocellular carcinoma registry study interim results: a multicenter study of the safety, feasibility, and outcomes of the SIS expandable-tip microcatheter in DEB-TACE
Kapoor et al.
September 2017
PlOS One
Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma
Alexander Y. Kim, CShelby Frantz, Pranay Krishnan, Danielle DeMulder, Theresa Caridi, George Emmett Lynskey, James B. Spies
March 2017
SIR Abstract
Surefire Medical’s Infusion Technology Studied for Treatment of Primary Liver Cancer
Kim et al.
August 2015
Cardiovascular Interventional Radiology
End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
Titano et al.
May 2015
Journal of Vascular and Interventional Radiology
The Impact of an Antireflux Catheter on Target Volume Particulate Distribution in Liver-Directed Embolotherapy: A Pilot Study
Van de Hoven et al.